FDA approves Trikafta treatment for patients with most common cystic fibrosis mutation

Cystic fibrosis is a life threatening disease that causes irregular amounts of mucus to build up in the digestive tract and lungs, which further results in digestive and respiratory problems. A mutation in the CFTR gene of protein is the cause of cystic fibrosis. Trikafta combines the three drugs elexacaftor, ivacaftor, and tezacaftor to target the CFTR gene in order to increase the functionality of the protein. FDA has approved Trikafta for patients 12 years and older and will allow for treatment of 90% of patients with cystic fibrosis, which is 27,000 patients in the US. For more information click here.